With a market capitalization of $18.4 billion and an impressive EBITDA of $1.69 billion in the last twelve months, ICON's position as a key player in accelerating drug development for biopharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback